LICENSING
Project Name Therapeutic Areas Indications Stage Right Available
Anti-B7H3 ADC Oncology/Cancer Broad cancer PCC Global
Best-in-class IRAK4 degrader Psoriasis,RA,IBD PCC Global
NF-κB inhibitor Oncology/Cancer Cancer cachexia PCC Global
See in our "Antibody Licensing" platform Next to "Licensing" Tab in the top PCC
ActRIIB inhibitor Oncology/Cancer Cancer cachexia Preclinical Global
B7H3/PD-L1 bsAb Oncology/Cancer Advanced solid tumor Preclinical Global
BAFFR/CD3 bsAb Oncology/Cancer B-cell lymphoma Preclinical Global
BCL-XL PROTAC Oncology/Cancer,Ophthalmology disease small cell lung cancer,non-small cell lung cancer,lymphoma,acute myeloid leukemia,acute lymphocytic leukemia,diabetic macular edema,diabetic retinopathy Preclinical Global
CCR8 mAb (sequence cooperation) Oncology/Cancer Solid Tumor Preclinical Global
FRa BsAb (sequence cooperation) Oncology/Cancer Ovarian cancer Preclinical Global
GCC mAb (sequence cooperation) Oncology/Cancer Solid Tumor Preclinical Global
GLP-1/GIP/FGF21 fusion protein Metabolic disease NASH,Type 2 diabetes,hyperlipidemia Preclinical Global  (except China)
GPCR selective agonist Immunological disease Duchenne muscular dystrophy,SLE Preclinical Global
B7H3+CD3 BsAb Oncology/Cancer Solid Tumor IND Global
CD19 mAb Immunological disease autoimmune disease IND Global
  • 1
  • 2
  • 3
Boston
|
San Jose
|
Newark
|
Frankfurt
London
|
Basel
|
Beijing
|
Shanghai
Hangzhou
|
Suzhou
Stay Connected and Get Updates
Subscribe newsletter